Loading…
← CockpitCompetitor Analysis › 6748.TWO ACRO Biomedical Co., Ltd.Open in the cockpit ↗

ACRO Biomedical Co., Ltd.6748.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Medical Specialties
Momentum leader 98
Mkt cap
$377M
US dollars, full cap
$/day
$1.56M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-46.2 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · TWDNT$178.00
1D-3.0%
1W+5.0%
1M-8.5%
3M+1.7%
6M+158.0%
YTD+169.7%
1Y+180.2%
ATR %8.4%
52w lowhigh42.6% off high

What ACRO Biomedical does

No business profile yet.

ACRO Biomedical at a glance

Size ACRO Biomedical (6748.TWO) is a Taiwan Health Care company (Medical Specialties) with a market value of $377M, the 529th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$178.00 on 18 Nov 2026.

Performance Over six months the shares gained 158.0%, against -18.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 44.5% over the last twelve months (peer median +7.1%); the operating margin is -178.3% (peer median 12.2%).

Valuation It trades at 218.3× enterprise value to sales against a peer median of 2.7× (most expensive of 21).

Capital Return on invested capital runs 46.2 points below its cost of capital (5.0% WACC).

Relative performance

20040021 May 202621 Aug 202618 Nov 20266748.TWO 258Peer median 83
Six months, rebased to 100: ACRO Biomedical against the median of its 20 peers (local-currency closes).

ACRO Biomedical financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$52.8MNT$38.3MNT$44.2MNT$51.1MNT$27.6M
Revenue growth—-14%-13%+85%—
Gross profitNT$28.0MNT$12.2MNT$17.8MNT$31.0MNT$7.37M
EBITDA-NT$78.2M-NT$75.7M-NT$51.2M-NT$37.7M-NT$53.6M
Net income-NT$78.8M-NT$82.7M-NT$62.1M-NT$41.4M-NT$60.9M
Free cash flow-NT$81.5M-NT$61.8M-NT$73.7M-NT$68.6M-NT$50.3M
Capital expenditureNT$11.3MNT$15.4MNT$32.6MNT$22.5MNT$4.44M
Total debtn/aNT$10.6MNT$15.8MNT$21.7MNT$11.8M

Quarterly statements and history in the cockpit →

ACRO Biomedical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%605186300562041830BWAY4736CVSBS1609688338458870MASS3002386748.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. ACRO Biomedical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×100×200×2041605186300562041830BWAY4736CVSBS002022CERS4588703002386881336748.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ACRO Biomedical is the large dot.

ACRO Biomedical competitors and peer comparison

How ACRO Biomedical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ACRO Biomedical against its 20 peers (data as of 18 Nov 2026)
Measure6748.TWOPeer medianRank in peer set
1-month return-8.5%-11.6%6th highest of 21
6-month return+158.0%-18.1%highest of 20
Distance from 52-week high-42.6%-44.8%9th highest of 21
Revenue growth (TTM)+44.5%+7.1%2nd highest of 21
Operating margin-178.3%12.2%2nd lowest of 21
EV / Sales218.3×2.7×most expensive of 21
ROIC minus cost of capital-46.2 pp+7.3 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%7.8×n/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
InBody 041830.KSSouth Korea$380M-13%+22%22%1.4×-10.3%+16.9%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Taidoc Technology 4736.TWTaiwan$387M0%0%19%1.8×-9.5%-6.6%
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a
Stratec SBS.DEGermany$365M+63%-6%4%1.8×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%3.7×-13.1%+36.8%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%1.7×n/an/a
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%4.2×5.7%+3.4%
Cerus CERSUnited States$392M-28%+14%-12%1.8×n/an/a
SEERS 458870.KSSouth Korea$392M-70%+174%37%5.5×-6.3%+247.0%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%1.0×-17.6%+15.4%
908 Devices MASSUnited States$396M+36%+14%-33%4.6×41.7%+15.9%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%5.4×18.4%+4.4%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%1.1×-12.7%-1.3%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%

Questions

Which companies are ACRO Biomedical's closest peers?
The cockpit's peer set: Medcaptain Medical Technology (2041.HK), Shanghai General Healthy Information & Technology (605186.SS), Guangdong Transtek Medical Electronics (300562.SZ), InBody (041830.KS), Brainsway Ltd Sponsored ADR (BWAY), Taidoc Technology (4736.TW), CapsoVision (CV), Stratec (SBS.DE).
Is ACRO Biomedical expensive compared with its peers?
On ev / sales it trades at 218.3× against a peer median of 2.7×, most expensive of 21 in its peer set.
How has ACRO Biomedical stock performed?
Over six months to 18 Nov 2026 the shares returned +158.0% against -18.1% for the median peer; over one year +180.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.